Gastroenterology/Bariatrics Clinical Trial - Abbvie - M14-431

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03345836

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).

Drug

Drug: upadacitinib, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Weight loss Crohn's Disease

Keywords

Crohn's Disease | Weight loss | Abbvie | upadacitinib